Dana L Buchanan, DO | |
1441 Florida Ave, Modesto, CA 95350-4405 | |
(209) 578-1211 | |
Not Available |
Full Name | Dana L Buchanan |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Experience | 21 Years |
Location | 1441 Florida Ave, Modesto, California |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174539423 | NPI | - | NPPES |
00AX94690 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 20A9469 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Memorial Medical Center | Modesto, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Cep America - California | 6103739131 | 954 |
Golden Valley Health Center | 4183527187 | 65 |
News Archive
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Critical Path Institute's Data Collaboration Center and the Friedreich's Ataxia Research Alliance today announced the launch of the Friedreich's Ataxia Integrated Clinical Database.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.
A new head-mounted display system lets anesthesiologists keep an eye on critical monitoring data during surgery—without having to turn their attention away from the patient, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
› Verified 6 days ago
Entity Name | Cep America - California |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Critical Path Institute's Data Collaboration Center and the Friedreich's Ataxia Research Alliance today announced the launch of the Friedreich's Ataxia Integrated Clinical Database.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.
A new head-mounted display system lets anesthesiologists keep an eye on critical monitoring data during surgery—without having to turn their attention away from the patient, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
› Verified 6 days ago
Entity Name | Golden Valley Health Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356445753 PECOS PAC ID: 4183527187 Enrollment ID: O20040128000641 |
News Archive
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Critical Path Institute's Data Collaboration Center and the Friedreich's Ataxia Research Alliance today announced the launch of the Friedreich's Ataxia Integrated Clinical Database.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.
A new head-mounted display system lets anesthesiologists keep an eye on critical monitoring data during surgery—without having to turn their attention away from the patient, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dana L Buchanan, DO 2100 Powell St, Suite 900, Emeryville, CA 94608-1826 Ph: (510) 350-2777 | Dana L Buchanan, DO 1441 Florida Ave, Modesto, CA 95350-4405 Ph: (209) 578-1211 |
News Archive
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Critical Path Institute's Data Collaboration Center and the Friedreich's Ataxia Research Alliance today announced the launch of the Friedreich's Ataxia Integrated Clinical Database.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.
A new head-mounted display system lets anesthesiologists keep an eye on critical monitoring data during surgery—without having to turn their attention away from the patient, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
› Verified 6 days ago
John Joseph Gallo, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3800 Dale Rd, Modesto, CA 95356 Phone: 209-557-1000 | |
Pallavi Sharma, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Coffee Rd, Modesto, CA 95355 Phone: 209-521-6097 | |
Phillip Michael Chan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1441 Florida Ave, Emergency Department, Modesto, CA 95350 Phone: 650-388-6383 | |
Dr. Paul Anthony Raykov, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-735-5000 | |
Gregory P. Bowerman, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Coffee Rd, Modesto, CA 95355 Phone: 209-569-7600 | |
Christopher Samuel Lau, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-735-6810 | |
Sushma V Shah, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4301 N Star Way, Modesto, CA 95356 Phone: 209-342-2300 Fax: 209-524-4240 |